Both intra-and extracellular calcium play multiple roles in the physiology and pathophysiology of cardiomyocytes, especially in stimulus-contraction coupling. The intracellular calcium level is closely controlled through the concerted actions of calcium channels, exchangers, and pumps; however, the expression and function(s) of the so-called calcium-sensing receptor (CaR) in the heart remain less well characterized. The CaR is a seven transmembrane receptor, which, in response to noncovalent binding of extracellular calcium, activates intracellular effectors, including G proteins and extracellular signalregulated kinases (ERK1/2 
INTRODUCTION
The pivotal role of calcium in the normal physiology and pathophysiology of the cardiomyocyte is well known (41) . Both intra-and extracellular calcium play multiple roles in cardiac myocytes, especially in stimulus-contraction coupling. In normal physiology calcium acts via rapid changes in intracellular calcium as a result of changes in the activities of calcium channels, exchangers and pumps, i.e. calcium is a so-called second messenger. However, it is conceivable that calcium also may act as a first messenger through an extracellular signaling mechanism. The calcium receptor (CaR) senses the extracellular calcium level and can tell the cell the exact level of calcium outside the cell. The change in calcium levels will be transformed into activation of intracellular signaling pathways that will induce downstream effects on the cell.
The CaR belongs to family C II of the superfamily of seven transmembrane (7TM) receptors, also termed G protein-coupled receptors (5) . The human CaR is 1078 amino acid residues long and, like other 7TM receptors, has three structural domains: (1) an unusually large extracellular domain (ECD), characteristic of the family C 7TM receptors; (2) a transmembrane domain (TMD), and (3) an intracellular domain (ICD), which is the hydrophilic C-terminus of the protein. A wide range of intracellular signaling pathways of the CaR have been identified, including phospholipase C (PLC), which stimulates inositol phosphate production, and mitogen-activated protein kinases (MAPK)(28). Although the major ligand of the CaR is extracellular calcium, it is a promiscuous receptor that recognizes many ligands (28). CaR agonists are divided into type I, which are direct agonists, and type II, which work as allosteric modulators, i.e., they require the presence of calcium to activate the receptor. The best described CaR function is its regulation of the secretion of parathyroid hormone (4), a key calciumregulating hormone in the calcium homeostatic system. Type II CaR agonists, termed calcimimetics, have been introduced in the treatment of uremic hyperparathyroidism (24).
The calcimimetics bind to the TMD of the CaR and increase its sensitivity to the calcium CaR agonist induced the production of inositol phosphate (IP), suggesting that the CaR is linked to the PLC pathway. Furthermore, a recent study elegantly showed that the CaR is also present in the endothelial cells of mesentery and coronary arteries, and that the stimulation of the receptor induced hyperpolarisation of the vascular smooth muscle cells (36). This study indicates that CaR is present in the heart. The function of the CaR in heart in normo-and pathophysiology remains to be clarified.
It is thought that neonatal cardiomyocytes are terminally differentiated, though this view has recently been challenged (6, 7) . However, DNA synthesis is observed in neonatal cardiac myocytes undergoing hypertrophy (7), perhaps because hypertrophy of different cells involves a partial progression through the cell cycle (3). Other G-protein coupled receptors such as angiotensin receptor type 1 and adrenergic receptors are known to induce hypertrophy in this primary cell culture (6) .
We hypothesized that the CaR is also functionally expressed in rat neonatal cardiomyocytes and that it regulates DNA synthesis. Thus, the aim of this study was to characterize the CaR in myocardial cells, to identify its downstream intracellular signaling pathways, and, finally, to investigate whether the CaR plays a role in regulating DNA synthesis of cardiomyocytes.
METHOD AND MATERIALS

Materials
Polyclonal antisera against phosphorylated and nonphosphorylated ERK1/2 were purchased from New England Biolabs (Beverly, MA). The enhanced chemiluminescence kit Supersignal was purchased from Pierce (Rockford, IL), and other reagents were from Sigma Chemical (St. Louis, MO).
Neonatal ventricular myocyte culture
Neonatal ventricular cardiomyocytes were prepared from 1-to 5-day-old neonatal Wistar rats (University of Copenhagen, Denmark) by a modification of a previously described method (27) . Rats were handled in accordance with local institutional guidelines. Cells were plated at a density of 5 ×10 4 cells/cm 2 in minimal essential medium (MEM) supplemented with 1% L-glutamine, 0.1 mM bromodeoxyuridine, 0.15 mM vitamin B12, 1 µg/ml insulin, and 6250 U/ml penicillin. Cell culture plates were precoated with 8% fetal calf serum for 5 h at 37 °C.
Immunofluorescence
Cells cultured on coverslips for 3 days were fixed with 4% formaldehyde.
To detect CaR-positive cells, we performed immunohistochemical studies using a monoclonal anti-CaR LRG antibody (peptide sequence used to raise this antibody was LRGHEESGDRFSNSSTAF) and a polyclonal anti-CaR FF7 antibody (peptide sequence used to raise this antibody was HNGFAKEFWEETFNC) as previously described (20) .
Actin was stained with 0.4 µg/ml TRITC-labeled phalloidin (Sigma, USA). 
Western blot analysis for phosphoERK1/2 and total ERK1/2
For determination of ERK1/2 phosphorylation and total ERK1/2, a monolayer of neonatal ventricular cardiomyocytes was plated 1.5 million cells/well on six-well plates.
After 72 hours in MEM, cells were incubated for 18 h in serum-free, Ca 
IP Assay
Inositol phosphate (IP) assay-Briefly, neonatal ventricular cardiomyocytes were plated in 12-well plates (10 6 cells/well) and grown as described above in medium containing 5% FCS for 72 h. Next, 16 h before stimulation, the medium was replaced with inositol-free DMEM supplemented with 5% FCS and myo-(2-3 H)-inositol (1µCi/ml) (Amersham). The accumulation of inositol phosphates was measured as described previously (12, 16) .
Infecting neonatal ventricular cardiomyocytes with CaR constructs in rAAV
High-efficiency gene transfer into neonatal ventricular cardiomyocytes was accomplished by a recombinant adeno-associated virus (rAAV)-based method. The CaR sequence with a naturally occurring, dominant-negative mutation (R185Q), as well as the same vector containing the cDNA encoding the beta-galactosidase gene, were under the control of a cytomegalovirus immediate-early (CMV-IE) promoter element, and were packaged as previously described (37) . The beta-galactosidase served as the control for nonspecific effects of rAAV infection. Cells were seeded (0.2 million cells/well) in 12-well plates in 0.5 ml of growth medium and cultured for 48 h. About 1000 virus particles/cell were used to infect each well as previously described(30). Cells were washed once with serum-free MEM. Virus particles were then added, and the culture was incubated for 90 min in serum-free medium at 37°C in a cell-culture incubator. Equal volumes of MEM containing 20% serum were added to the cells to achieve a final serum concentration of 10%. The cells were then cultured for 48 h, and experiments with calcium were performed as described above.
DNA synthesis assay
Neonatal ventricular cardiomyocytes cells were plated at 0.2 million cells/well in 12-well plates in the MEM described above, containing 0.1% fetal bovine serum. The cells were cultured for 48 h, and the medium was changed to serum-free, Ca
2+
-free DMEM containing 4 mM L-glutamine, 0.2% BSA, and 0.5 mM CaCl 2 . Calcium (0.5-10 mmol/l) or angiotensin (10 -7 mol/l) was added alone or with calcimimetic. 24 h later ( 3 H)-thymidine (1 µl/ml; 50 µCi/ml) was added, and the cells were cultured again for 20 h.
Twenty hours after application of the ( 3 H)-thymidine, the cells were assayed as described previously(29).
Data Analysis
All data were analyzed with GraphPad Prism. For the IP measurements, all experimental values were compared with the described controls using a two-tailed, unpaired Student's t-test. Data for DNA synthesis were analyzed with a two-way ANOVA followed by a Tukey-Kramer multiple-comparison post hoc test. Data are presented as mean ± SEM. A P value of < 0.05 was considered to represent a statistically significant difference.
RESULTS
CaR mRNA and protein are present in neonatal ventricular cardiomyocytes.
The existence of the CaR in cardiomyocytes could have a substantial impact on our view of the mechanisms underlying the effects that extracellular calcium have on the heart. We therefore investigated whether the mRNA of the CaR was expressed in neonatal ventricular cardiomyocytes. Using one-step RT-PCR with primers previously
published (26), we showed the amplification of a 331-bp product (figure 1a); sequencing of this cDNA product revealed it to be more than 99% homologous to the cDNA for the rat CaR. To document CaR-protein expression, immunostaining was performed on neonatal ventricular cardiomyocytes with two different anti-CaR antibodies. The two antibodies, both targeting the extracellular domain of the CaR, bound to the neonatal ventricular cardiomyocytes as visualized by confocal microscopy (figure 1b and c).
Immunostaining was observed both on the cell surface and intracellularly. Only faint staining occurred when the primary antibodies were omitted.
The CaR promotes the production of inositol phosphates (IP)
The CaR is linked to the phospholipase C/IP pathway in most cells(28). We therefore investigated whether stimulation with calcium would induce the accumulation of IPs in neonatal ventricular cardiomyocytes. In a concentration-dependent manner, calcium at 3, 6, and 10 mM Ca 2+ o increased IP accumulation by 16% ± 2% (mean ± SEM), 31% ± 2%, and 51% ± 2 %, respectively, compared with neonatal ventricular cardiomyocytes treated with 0.5 mM Ca 2+ o (figure 2a; P<0.005). Since the action of calcium may not be specific for the CaR, we investigated whether a selective allosteric activator of the receptor, AMG 073(24), which is currently used in the treatment of uremic hyperparathyroidism, would potentiate the calcium response. As shown in figure   2b , the addition of 3 µM AMG 073 increased the IP accumulation by 33% ± 2 % at 3 mM Ca 2+ o and 50% ± 2 % at 6 mM Ca 
CaR stimulation in neonatal ventricular cardiomyocytes induces ERK1/2 activation
ERK1/2 is a component of an important intracellular signaling pathway from the cell surface to the nucleus, which is known to be downstream of the CaR and is a key player in cell cycle regulation. ERK1/2 is activated by phosphorylation of the protein.
Previously, we found that the EC 50 for CaR-stimulated PTHrP secretion in rat H-500
Leydig cancer cells was 3-4 mM calcium (26) . In a pilot study investigating the effect of Ca 2+ o on ERK1/2 phosphorylation, the neonatal ventricular cardiomyocytes showed a concentration-dependent response between 0.5 and 10 mM Ca o DNA synthesis was reduced to 65% ± 9% and 61% ± 11% respectively, compared with that at 0.5 mM Ca 2+ o .(P<0.01 and P<0.001). There was no effect on cell number at any of the calcium concentrations used, as assessed by cell counting (data not shown).
Type II agonist of the CaR suppresses DNA synthesis in neonatal ventricular cardiomyocytes
We again utilized the type II calcimimetic AMG 073 to assess the CaR's role in the biphasic actions of calcium on DNA synthesis in neonatal ventricular cardiomyocytes. In the presence of 3 µM AMG 073, DNA synthesis at 0.5, 3, or 6 mM Ca 2+ o was reduced to 39% ± 4%, 61% ± 9%, and 12% ± 5 %, respectively, compared with that at 0.5 mM Ca (15) . On the contrary, the calcimimetic inhibited DNA synthesis at all levels of calcium. The difference in the effects of the two CaR ligands may be explained by differences in intracellular signal pathways that they activate, e.g., the duration of ERK1/2 activation. Alternatively, the effects of 3 mM calcium might not be mediated through the CaR.
Interestingly, in utero the fetus is kept in a hypercalcemic state due to a placental calcium pump (34) . This is important as the cells studied here are neonatal 
